Full-Time

Associate Director

Clinical Quality Assurance

Vera Therapeutics

Vera Therapeutics

201-500 employees

Develops therapies for immunologic diseases

Compensation Overview

$140k - $210k/yr

+ Bonus + Equity Grants

Remote in USA

Remote

Bachelor's, Master's, PhD

Category
QA & Testing (1)
Required Skills
Risk Management
Google Cloud Platform

Get referred to Vera Therapeutics

See people who can refer or advise you

Requirements
  • Bachelor’s degree in life sciences, pharmacy, or related scientific discipline required. Advanced degree preferred.
  • Approximately 8+ years of industry experience, including leadership in clinical quality oversight or quality governance.
  • Strong applied knowledge of global GxP regulations applicable to clinical development, including Good Clinical Practice (GCP), Good Pharmacovigilance Practice (GVP), Good Laboratory Practice (GLP); GMP experience is not required for this role.
Responsibilities
  • Serve as the Clinical Quality Assurance representative on assigned clinical study teams, providing proactive guidance to ensure clinical trial conduct aligns with GCP and regulatory expectations.
  • Provide oversight of clinical quality events, investigations, and CAPAs, ensuring appropriate root cause analysis, corrective actions, and identification of systemic quality trends.
  • Analyze quality signals across studies, vendors, and operational processes to identify emerging risks and recommend mitigation strategies.
  • Contribute to governance of the clinical audit program, including risk-based selection of audits and oversight of Audit CAPA follow-up. Execution of audits is performed by the audit function.
  • Serve as a quality interface with CROs and vendor quality representatives to ensure appropriate management and resolution of quality issues.
  • Support inspection readiness activities and provide first-line Clinical QA support during sponsor regulatory inspections, including preparation and follow-up actions.
  • Review and provide input on new or revised SOPs and controlled documents to ensure alignment with regulatory requirements and consistency across organizational procedures.
  • Provide input on training assignments and training matrices to ensure procedures are appropriately implemented across functional roles.
  • Participate in process improvement initiatives that support the development and strengthening of the Quality Management System, including the evaluation, assessment, and implementation of quality governance, processes, and systems.
Desired Qualifications
  • Relevant certifications such as RQAP, CQA, CCRC, or RAC are considered a plus.
  • Quality management and oversight of clinical trials; Quality event and CAPA management; Regulatory inspection readiness and inspection support; Risk-based quality management approaches; Planning of clinical audits (including sites, internal audits); Developing metrics and reviewing issues for quality signals and trends; SOP governance through controlled document reviews; Training matrix or training governance activities.
  • Bachelor’s degree in life sciences, pharmacy, or related scientific discipline preferred.
  • Advanced degree preferred.

Vera Therapeutics is a clinical-stage biotechnology company developing therapies for immunological diseases, with a focus on IgA nephropathy and BK virus management. Its lead asset, MAU868, is a neutralizing antibody that targets BK virus and is developed under an exclusive worldwide license from Pfizer. The company differentiates itself through the Pfizer license and a strategy that emphasizes licensing and commercialization to bring therapies to immunocompromised patients, especially those undergoing organ or stem cell transplants. The goal is to improve outcomes for patients with immunologic and rare diseases by translating research into accessible treatments and building a high-performance organization.

Company Size

201-500

Company Stage

IPO

Headquarters

Brisbane, California

Founded

2016

Get referred to Vera Therapeutics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA approval on July 7, 2026 opens immediate U.S. revenue and launch execution.
  • ORIGIN 3 eGFR results arrive in Q3 2026, enabling full-approval filing.
  • Vera held $596.8 million cash and a $500 million Oxford facility in March 2026.

What critics are saying

  • Novartis won full IgAN approval July 17, 2026, stealing physician attention and formulary slots.
  • Vertex's povetacicept faces a November 30, 2026 PDUFA, compressing Vera's first-mover advantage.
  • ORIGIN 3 confirmatory data controls TRUTAKNA's future; failure triggers withdrawal and crushes the franchise.

What makes Vera Therapeutics unique

  • TRUTAKNA became the first FDA-approved dual BAFF/APRIL IgAN therapy on July 7, 2026.
  • Patients self-inject weekly at home, reducing infusion-center dependence and boosting convenience.
  • Vera controls atacicept, VT-109, and MAU868 worldwide, with Stanford-backed BAFF/APRIL science.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Sabbatical Leave

Hybrid Work Options

Stock Options

Company Equity

401(k) Retirement Plan

401(k) Company Match

Performance Bonus

Profit Sharing

Conference Attendance Budget

Training Programs

Tuition Reimbursement

Professional Certification Support

Mentorship Program

Wellness Program

Mental Health Support

Gym Membership

Commuter Benefits

Phone/Internet Stipend

Home Office Stipend

Legal Services

Employee Discounts

Company Social Events

Adoption Assistance

Childcare Support

Elder Care Support

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Growth & Insights and Company News

Headcount

6 month growth

6%

1 year growth

2%

2 year growth

5%
Yahoo Finance
Jul 9th, 2026
Vera Therapeutics appoints Nancy Boman as chief regulatory officer, William Turner to retire

Vera Therapeutics has appointed Nancy Boman as Chief Regulatory Officer, replacing William Turner, who is retiring after helping secure accelerated approval for the company's first therapy, TRUTAKNA (atacicept-vymj), for IgA nephropathy. Turner will transition to a Strategic Advisor role in the third quarter. Boman brings over 25 years of regulatory affairs experience. She previously served as Chief Regulatory Officer at Kyverna Therapeutics, Adicet Bio, Encoded Therapeutics, and Novartis Gene Therapies. She also held leadership positions at Amgen, Genentech, and Alder. The Brisbane, California-based commercial-stage biotechnology company plans to pursue new indications for TRUTAKNA in other autoimmune kidney diseases whilst developing approval pathways for other molecules in its pipeline.

Associated Press
Jul 7th, 2026
FDA approves Vera's TRUTAKNA for IgA nephropathy, first BAFF and APRIL inhibitor

The US Food and Drug Administration has granted accelerated approval to Vera Therapeutics' TRUTAKNA for treating adult patients with primary IgA nephropathy at risk for disease progression. TRUTAKNA is the first therapy that binds both B-cell activating factor and A proliferation-inducing ligand, targeting immunological drivers of the disease. In the interim analysis of the ongoing ORIGIN 3 trial, participants achieved a 46% reduction from baseline in proteinuria, with a 42% reduction compared to placebo at 36 weeks. The therapy is administered as a 150 mg subcutaneous injection once weekly via an autoinjector at home. The accelerated approval is based on proteinuria reduction. Continued approval depends on verification of clinical benefit in the ongoing trial, with results expected in Q3 2026.

Associated Press
May 7th, 2026
Vera Therapeutics receives FDA priority review for IgAN drug, eyes July approval

Vera Therapeutics, a biotechnology company developing treatments for immunological diseases, reported a first-quarter net loss of $121 million, or $1.69 per share, compared to a $51.7 million loss in the same period last year. The FDA granted priority review to Vera's biologics licence application for atacicept, an investigational treatment for IgA Nephropathy in adults, with a target decision date of 7 July 2026. The company is preparing for a mid-2026 US commercial launch pending regulatory approval. Vera reported $596.8 million in cash, cash equivalents and marketable securities as of 31 March 2026, which it believes will fund operations beyond potential approval and commercial launch. The company anticipates initial results from its PIONEER Phase 2 trial in the second quarter of 2026.

American Press
May 4th, 2026
Vera Therapeutics to participate in the Bank of America Securities 2026 Health Care Conference.

Vera Therapeutics to participate in the Bank of America Securities 2026 Health Care Conference. GlobeNewswire | Vera Therapeutics Today at 4:30am PDT BRISBANE, Calif., May 04, 2026 (GLOBE NEWSWIRE) - Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will present at the Bank of America Securities 2026 Health Care Conference, which is taking place in Las Vegas, NV from May 12-14, 2026. The management team will also participate in one-on-one investor meetings. Presentation Details: Date: Wednesday, May 13, 2026 Time: 4:20 PM PDT Webcast: https://bofa.veracast.com/webcasts/bofa/healthcare2026/24Ty86.cfm A replay of the event will be available for 90 days and can be accessed by visiting the "Investor Calendar" section of the Vera Therapeutics website. About Vera Therapeutics Vera Therapeutics is a biotechnology company focused on developing treatments for serious immunological diseases. Vera Therapeutics' mission is to advance treatments that target the source of disease in order to change the standard of care for patients. Vera Therapeutics' lead product candidate is atacicept, a fusion protein self-administered at home as a subcutaneous once weekly injection that blocks both B-cell Activating Factor (BAFF) and A Proliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgA nephropathy (IgAN) and lupus nephritis. Beyond IgAN, Vera Therapeutics is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove clinically meaningful. In addition, Vera Therapeutics holds an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B-cell-mediated diseases. Vera Therapeutics is also evaluating the development of MAU868, a monoclonal antibody designed to neutralize infection with BK virus, which can have devastating consequences in kidney transplant recipients. Vera Therapeutics retains all global developmental and commercial rights to atacicept, VT-109, and MAU868. For more information, please visit www.veratx.com. Forward-looking Statements Statements contained in this press release regarding matters, events or results that may occur in the future are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, Vera Therapeutics' plans, commitments, aspirations and goals related to its product candidates. Words such as "anticipate," "believe," "expect," "may," "plan," "potential," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Vera Therapeutics' current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks related to the regulatory approval process, results of earlier clinical trials may not be obtained in later clinical trials, preliminary results may not be predictive of topline results, risks and uncertainties associated with Vera Therapeutics' business in general, the impact of macroeconomic and geopolitical events, and the other risks described in Vera Therapeutics' filings with the U.S. Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. Vera Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. This is a paid placement. For further inquiries, please contact GlobeNewswire directly.

Associated Press
Mar 27th, 2026
Vera Therapeutics grants stock options and RSUs to new Chief Legal Officer

Vera Therapeutics has granted inducement awards to Jane Wright-Mitchell, its new Chief Legal Officer, consisting of non-qualified stock options to purchase 56,850 shares and restricted stock units underlying 42,403 shares of Class A common stock. The Compensation Committee approved the awards on 23 March 2026 under the company's 2024 Inducement Plan. The stock options have an exercise price of $40.73 per share and will vest over four years, with 25% vesting after the first anniversary and the remainder vesting monthly over 36 months. The RSU award will vest 25% annually over four years starting 20 May 2026. Vera Therapeutics is a late clinical-stage biotechnology company developing treatments for immunological diseases, with atacicept as its lead product candidate targeting autoimmune diseases including IgAN and lupus nephritis.